New research to be presented at this year's European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces body weight and waist circumference regardless of the length of time the person has been living with overweight or obesity.
Postmenopausal women on hormone therapy had higher total body weight loss with semaglutide for up to 12 months vs. no hormone therapy.
Bariatric surgery may result in significant cardiometabolic improvements, particularly among younger, female, or white people and those without comorbidities, according to new research, titled "Cardiometabolic Improvements After Metabolic Surgery and Related Pre-surgery Factors," published in the Journal of the Endocrine Society.
An experimental new weight loss pill from Danish pharmaceutical giant Novo Nordisk could be twice as effective as its blockbuster Ozempic and Wegovy jabs, early results from a small trial have suggested, sending the firm's shares soaring.
New research being presented at this year's European Congress on Obesity (ECO) in Venice, Italy (12-15 May), suggests that replacing sugar-sweetened food and drinks with low/no energy sweetened products can help weight control for at least one year after rapid weight loss in adults, without increasing the risk of type 2 diabetes or cardiovascular disease.
